Feb 3 (Reuters) - Indian drugmaker Mankind Pharma reported a higher third-quarter profit on Tuesday, driven by strong ...

Analysts said back-to-back trade deals with the U.S. and EU could lift pharma, manufacturing and IT stocks.

As supply chain vulnerabilities intensify and competition accelerates, the cost of this underutilization could risk India's ...

With the US accounting for nearly 35% of India’s overall pharma shipments of over $30 billion in FY24-25, the move is ...

The so-called “mother of all deals” lowers import tariffs on European pharma exports from 11% to zero and also eliminates ...

Europe remains a large but under-penetrated destination for Indian drugmakers. Data from the Pharmaceuticals Export Promotion ...

Besides Sun Pharma, a growing roster of Indian drugmakers is lining up cheaper generic versions of semaglutide ahead of the ...

Export-focused stocks jump on optimism around Europe exposure, as analysts suggest textiles, pharmaceuticals and chemicals ...

Jan 23 () - Sun ​Pharmaceutical ‌Industries, India's ‌top drugmaker by ⁠revenue, ‌said on Friday ‍that it has ​received ‌regulatory approval to manufacture and sell ⁠generic ​semaglutide ​in India.

The proposed agreement aims to cut tariffs on medicines and medical devices, potentially lowering healthcare costs, while ...

By Bharath Rajeswaran Feb 1 (Reuters) - Indian benchmarks held on to modest gains in a special trading session on Sunday as ...

Shardul Nautiyal, Mumbai Monday, February 2, 2026, 08:00 Hrs [IST] ...